<DOC>
	<DOCNO>NCT02066870</DOCNO>
	<brief_summary>The NSCLC patient experience good clinical response EGFR-TKI inevitably develop acquire resistance . A great deal research focus issue . Arsenic trioxide show efficacy safety acute promyelocytic leukemia , multiple myeloma solid tumor . Moreover , preclinical study show arsenic trioxide reduce resistance tumor cell chemotherapy TKIs .</brief_summary>
	<brief_title>Icotinib Arsenic Trioxide Treating Non-small-cell Lung Cancer Patients With Resistance EGFR-TKI</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Histologically cytologically confirm stage IIIB/IV lung cancer EGFR mutation Progressed platinumbased chemotherapy The last antitumor therapy enter study must gefitinib , erlotinib icotinib , duration tumor response must less 4 month , duration stable disease must less 6 month With measurable disease conventional CT ) accord RECIST Criteria WHO performance status ( PS ) &lt; = 2 N &gt; =1.5×109/L , Plt &gt; =1.0×109/L , Hb &gt; =9g/dL ; AST &amp; ALT &lt; 2.5ULN ( without liver metastasis ) &lt; 5ULN ( liver metastasis ) .TBIL &lt; =1.5ULN . Signed date informed consent start specific protocol procedure . Allergic icotinib arsenic trioxide . Patients metastatic brain tumor symptom . Severe systemic disease control unstable uncompensated respiratory , cardiac , liver , renal disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Icotinib</keyword>
	<keyword>Arsenic Trioxide</keyword>
	<keyword>Resistance</keyword>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>